Summary:
In adults with type 2 diabetes treated with insulin and GLP-1 receptor agonists, Control-IQ+ automated insulin delivery (AID) significantly reduced HbA1c levels and insulin use without weight gain compared to standard insulin therapy plus GLP-1 receptor agonists, though it was associated with no increase in adverse events reported.
| PICO | Description |
|---|---|
| Population | Adults with type 2 diabetes undergoing insulin therapy and concomitant GLP-1 receptor agonist treatment. |
| Intervention | Automated insulin delivery using the Control-IQ+ system added to GLP-1 receptor agonist therapy. |
| Comparison | Conventional insulin therapy combined with GLP-1 receptor agonist treatment. |
| Outcome | The Control-IQ+ AID group demonstrated significant reductions in HbA1c levels and insulin dose requirements without statistically significant weight gain. No increased incidence of adverse events was observed, indicating added glycemic control benefits with maintained safety. |
Source: Timothy E Graham, et al. “Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes.” Read article here.
